Is CRIS or SGMO more profitable?

Curis has a net margin of -80.29% compared to Sangamo Therapeutics' net margin of -310.81%. Curis' return on equity of 0.00% beat Sangamo Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Curis -80.29% N/A -181.57% Sangamo Therapeutics -310.81% -2,662.06% -132.12%

Does the media favor CRIS or SGMO?

In the previous week, Curis had 1 more articles in the media than Sangamo Therapeutics. MarketBeat recorded 2 mentions for Curis and 1 mentions for Sangamo Therapeutics. Curis' average media sentiment score of 0.93 beat Sangamo Therapeutics' score of 0.00 indicating that Curis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Curis 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sangamo Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is CRIS or BOLT more profitable?

Curis has a net margin of -80.29% compared to Bolt Biotherapeutics' net margin of -455.15%. Curis' return on equity of 0.00% beat Bolt Biotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Curis -80.29% N/A -181.57% Bolt Biotherapeutics -455.15% -100.89% -48.23%

Which has better earnings & valuation, AMGN or CRIS?

Amgen has higher revenue and earnings than Curis. Curis is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Amgen $36.75B 5.22 $7.71B $14.37 24.72 Curis $9.44M 1.74 -$7.58M -$1.19 N/A

Is AMGN or CRIS more profitable?

Amgen has a net margin of 20.96% compared to Curis' net margin of -80.29%. Amgen's return on equity of 137.41% beat Curis' return on equity. Company Net Margins Return on Equity Return on Assets Amgen 20.96% 137.41% 13.28% Curis -80.29% N/A -181.57%

Does the media prefer AMGN or CRIS?

In the previous week, Amgen had 56 more articles in the media than Curis. MarketBeat recorded 58 mentions for Amgen and 2 mentions for Curis. Amgen's average media sentiment score of 1.30 beat Curis' score of 0.93 indicating that Amgen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amgen 47 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive Curis 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is CRIS or GILD more profitable?

Gilead Sciences has a net margin of 30.99% compared to Curis' net margin of -80.29%. Gilead Sciences' return on equity of 48.19% beat Curis' return on equity. Company Net Margins Return on Equity Return on Assets Curis -80.29% N/A -181.57% Gilead Sciences 30.99% 48.19% 18.28%

Does the media refer more to CRIS or GILD?

In the previous week, Gilead Sciences had 75 more articles in the media than Curis. MarketBeat recorded 77 mentions for Gilead Sciences and 2 mentions for Curis. Gilead Sciences' average media sentiment score of 1.31 beat Curis' score of 0.93 indicating that Gilead Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Curis 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Gilead Sciences 60 Very Positive mention(s) 3 Positive mention(s) 9 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media refer more to CRIS or VRTX?

In the previous week, Vertex Pharmaceuticals had 50 more articles in the media than Curis. MarketBeat recorded 52 mentions for Vertex Pharmaceuticals and 2 mentions for Curis. Vertex Pharmaceuticals' average media sentiment score of 1.24 beat Curis' score of 0.93 indicating that Vertex Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Curis 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vertex Pharmaceuticals 41 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Curis (CRIS) Competitors

$0.42 -0.01 (-1.29%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$0.42 +0.00 (+0.93%)

As of 06/12/2026 04:10 PM Eastern

Compare

CRIS vs. SGMO, BOLT, AMGN, GILD, and VRTX

Should you buy Curis stock or one of its competitors? MarketBeat compares Curis with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Curis include Sangamo Therapeutics (SGMO), Bolt Biotherapeutics (BOLT), Amgen (AMGN), Gilead Sciences (GILD), and Vertex Pharmaceuticals (VRTX). These companies are all part of the "biotechnology" industry.

How does Curis compare to Sangamo Therapeutics?

Curis (NASDAQ:CRIS) and Sangamo Therapeutics (NASDAQ:SGMO) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, risk, institutional ownership, profitability, valuation and earnings.

In the previous week, Curis had 1 more articles in the media than Sangamo Therapeutics. MarketBeat recorded 2 mentions for Curis and 1 mentions for Sangamo Therapeutics. Curis' average media sentiment score of 0.93 beat Sangamo Therapeutics' score of 0.00 indicating that Curis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Curis	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sangamo Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Curis currently has a consensus price target of $17.00, indicating a potential upside of 3,937.05%. Sangamo Therapeutics has a consensus price target of $5.50, indicating a potential upside of 3,542.38%. Given Curis' higher possible upside, equities research analysts clearly believe Curis is more favorable than Sangamo Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Curis	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
Sangamo Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

Curis has a net margin of -80.29% compared to Sangamo Therapeutics' net margin of -310.81%. Curis' return on equity of 0.00% beat Sangamo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Curis	-80.29%	N/A	-181.57%
Sangamo Therapeutics	-310.81%	-2,662.06%	-132.12%

30.0% of Curis shares are owned by institutional investors. Comparatively, 56.9% of Sangamo Therapeutics shares are owned by institutional investors. 5.4% of Curis shares are owned by company insiders. Comparatively, 4.1% of Sangamo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Curis has a beta of 3.05, suggesting that its share price is 205% more volatile than the broader market. Comparatively, Sangamo Therapeutics has a beta of 1.3, suggesting that its share price is 30% more volatile than the broader market.

Curis has higher earnings, but lower revenue than Sangamo Therapeutics. Sangamo Therapeutics is trading at a lower price-to-earnings ratio than Curis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Curis	$9.44M	1.74	-$7.58M	-$1.19	N/A
Sangamo Therapeutics	$39.55M	1.58	-$122.93M	-$0.38	N/A

Summary

Curis beats Sangamo Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Curis compare to Bolt Biotherapeutics?

Curis (NASDAQ:CRIS) and Bolt Biotherapeutics (NASDAQ:BOLT) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends, media sentiment and risk.

Curis has higher revenue and earnings than Bolt Biotherapeutics. Curis is trading at a lower price-to-earnings ratio than Bolt Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Curis	$9.44M	1.74	-$7.58M	-$1.19	N/A
Bolt Biotherapeutics	$7.70M	1.14	-$33.38M	-$16.33	N/A

Curis presently has a consensus target price of $17.00, suggesting a potential upside of 3,937.05%. Bolt Biotherapeutics has a consensus target price of $34.67, suggesting a potential upside of 660.23%. Given Curis' higher possible upside, research analysts clearly believe Curis is more favorable than Bolt Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Curis	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
Bolt Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Curis has a beta of 3.05, meaning that its share price is 205% more volatile than the broader market. Comparatively, Bolt Biotherapeutics has a beta of 1.12, meaning that its share price is 12% more volatile than the broader market.

30.0% of Curis shares are owned by institutional investors. Comparatively, 86.7% of Bolt Biotherapeutics shares are owned by institutional investors. 5.4% of Curis shares are owned by company insiders. Comparatively, 9.4% of Bolt Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Curis had 1 more articles in the media than Bolt Biotherapeutics. MarketBeat recorded 2 mentions for Curis and 1 mentions for Bolt Biotherapeutics. Bolt Biotherapeutics' average media sentiment score of 1.87 beat Curis' score of 0.93 indicating that Bolt Biotherapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Curis	Positive
Bolt Biotherapeutics	Very Positive

Curis has a net margin of -80.29% compared to Bolt Biotherapeutics' net margin of -455.15%. Curis' return on equity of 0.00% beat Bolt Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Curis	-80.29%	N/A	-181.57%
Bolt Biotherapeutics	-455.15%	-100.89%	-48.23%

Summary

Curis beats Bolt Biotherapeutics on 9 of the 16 factors compared between the two stocks.

How does Curis compare to Amgen?

Amgen (NASDAQ:AMGN) and Curis (NASDAQ:CRIS) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, dividends, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

Amgen has a beta of 0.42, indicating that its stock price is 58% less volatile than the broader market. Comparatively, Curis has a beta of 3.05, indicating that its stock price is 205% more volatile than the broader market.

Amgen has higher revenue and earnings than Curis. Curis is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amgen	$36.75B	5.22	$7.71B	$14.37	24.72
Curis	$9.44M	1.74	-$7.58M	-$1.19	N/A

76.5% of Amgen shares are owned by institutional investors. Comparatively, 30.0% of Curis shares are owned by institutional investors. 0.9% of Amgen shares are owned by company insiders. Comparatively, 5.4% of Curis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Amgen had 56 more articles in the media than Curis. MarketBeat recorded 58 mentions for Amgen and 2 mentions for Curis. Amgen's average media sentiment score of 1.30 beat Curis' score of 0.93 indicating that Amgen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amgen	47 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive
Curis	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Amgen currently has a consensus price target of $354.12, indicating a potential downside of 0.31%. Curis has a consensus price target of $17.00, indicating a potential upside of 3,937.05%. Given Curis' higher probable upside, analysts clearly believe Curis is more favorable than Amgen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amgen	2 Sell rating(s)	14 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	2.48
Curis	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67

Amgen has a net margin of 20.96% compared to Curis' net margin of -80.29%. Amgen's return on equity of 137.41% beat Curis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amgen	20.96%	137.41%	13.28%
Curis	-80.29%	N/A	-181.57%

Summary

Amgen beats Curis on 14 of the 17 factors compared between the two stocks.

How does Curis compare to Gilead Sciences?

Curis (NASDAQ:CRIS) and Gilead Sciences (NASDAQ:GILD) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, valuation, institutional ownership, earnings, profitability and risk.

Gilead Sciences has a net margin of 30.99% compared to Curis' net margin of -80.29%. Gilead Sciences' return on equity of 48.19% beat Curis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Curis	-80.29%	N/A	-181.57%
Gilead Sciences	30.99%	48.19%	18.28%

Gilead Sciences has higher revenue and earnings than Curis. Curis is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Curis	$9.44M	1.74	-$7.58M	-$1.19	N/A
Gilead Sciences	$29.44B	5.30	$8.51B	$7.34	17.11

Curis has a beta of 3.05, suggesting that its share price is 205% more volatile than the broader market. Comparatively, Gilead Sciences has a beta of 0.31, suggesting that its share price is 69% less volatile than the broader market.

Curis currently has a consensus target price of $17.00, indicating a potential upside of 3,937.05%. Gilead Sciences has a consensus target price of $156.93, indicating a potential upside of 24.95%. Given Curis' higher possible upside, equities analysts plainly believe Curis is more favorable than Gilead Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Curis	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
Gilead Sciences	0 Sell rating(s)	4 Hold rating(s)	25 Buy rating(s)	0 Strong Buy rating(s)	2.86

In the previous week, Gilead Sciences had 75 more articles in the media than Curis. MarketBeat recorded 77 mentions for Gilead Sciences and 2 mentions for Curis. Gilead Sciences' average media sentiment score of 1.31 beat Curis' score of 0.93 indicating that Gilead Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Curis	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Gilead Sciences	60 Very Positive mention(s)	3 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

30.0% of Curis shares are held by institutional investors. Comparatively, 83.7% of Gilead Sciences shares are held by institutional investors. 5.4% of Curis shares are held by insiders. Comparatively, 0.3% of Gilead Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Gilead Sciences beats Curis on 13 of the 16 factors compared between the two stocks.

How does Curis compare to Vertex Pharmaceuticals?

Curis (NASDAQ:CRIS) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, dividends, earnings, institutional ownership, risk, profitability, valuation and analyst recommendations.

In the previous week, Vertex Pharmaceuticals had 50 more articles in the media than Curis. MarketBeat recorded 52 mentions for Vertex Pharmaceuticals and 2 mentions for Curis. Vertex Pharmaceuticals' average media sentiment score of 1.24 beat Curis' score of 0.93 indicating that Vertex Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Curis	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vertex Pharmaceuticals	41 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Vertex Pharmaceuticals has a net margin of 35.51% compared to Curis' net margin of -80.29%. Vertex Pharmaceuticals' return on equity of 23.86% beat Curis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Curis	-80.29%	N/A	-181.57%
Vertex Pharmaceuticals	35.51%	23.86%	17.13%

Curis has a beta of 3.05, meaning that its share price is 205% more volatile than the broader market. Comparatively, Vertex Pharmaceuticals has a beta of 0.3, meaning that its share price is 70% less volatile than the broader market.

Curis currently has a consensus target price of $17.00, indicating a potential upside of 3,937.05%. Vertex Pharmaceuticals has a consensus target price of $555.91, indicating a potential upside of 24.95%. Given Curis' higher possible upside, equities analysts clearly believe Curis is more favorable than Vertex Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Curis	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
Vertex Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	22 Buy rating(s)	0 Strong Buy rating(s)	2.88

30.0% of Curis shares are owned by institutional investors. Comparatively, 91.0% of Vertex Pharmaceuticals shares are owned by institutional investors. 5.4% of Curis shares are owned by company insiders. Comparatively, 0.2% of Vertex Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Vertex Pharmaceuticals has higher revenue and earnings than Curis. Curis is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Curis	$9.44M	1.74	-$7.58M	-$1.19	N/A
Vertex Pharmaceuticals	$12.00B	9.41	$3.95B	$16.86	26.39

Summary

Vertex Pharmaceuticals beats Curis on 13 of the 16 factors compared between the two stocks.

Get Curis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRIS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CRIS vs. The Competition

Export

Metric	Curis	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$16.41M	$3.40B	$6.74B	$12.07B
Dividend Yield	N/A	2.25%	2.67%	5.65%
P/E Ratio	-0.35	19.82	24.19	24.42
Price / Sales	1.74	305.72	511.20	109.82
Price / Cash	N/A	123.04	43.54	55.64
Price / Book	1.00	8.32	10.65	6.80
Net Income	-$7.58M	$23.94M	$3.57B	$338.00M
7 Day Performance	-11.03%	3.53%	0.83%	2.68%
1 Month Performance	-15.78%	-1.43%	0.09%	2.15%
1 Year Performance	-82.81%	44.80%	25.18%	30.48%

Curis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CRIS Curis	2.6979 of 5 stars	$0.42 -1.3%	$17.00 +3,937.0%	-84.8%	$16.41M	$9.44M	N/A	60	Gap Down
SGMO Sangamo Therapeutics	1.7749 of 5 stars	$0.15 -15.7%	$5.50 +3,693.1%	-70.0%	$60.07M	$39.55M	N/A	480	Gap Up
BOLT Bolt Biotherapeutics	3.2197 of 5 stars	$4.76 +0.8%	$34.67 +628.9%	-26.8%	$9.29M	$7.70M	N/A	90
AMGN Amgen	3.809 of 5 stars	$345.54 -0.1%	$353.81 +2.4%	+19.5%	$186.68B	$36.75B	24.07	31,500	Trending News Analyst Forecast
GILD Gilead Sciences	4.919 of 5 stars	$125.16 -2.3%	$156.93 +25.4%	+12.1%	$155.40B	$29.44B	17.05	17,000	Trending News Analyst Forecast Options Volume Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CRIS) was last updated on 6/13/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Curis (CRIS) Competitors

CRIS vs. SGMO, BOLT, AMGN, GILD, and VRTX

How does Curis compare to Sangamo Therapeutics?

Summary

How does Curis compare to Bolt Biotherapeutics?

Summary

How does Curis compare to Amgen?

Summary

How does Curis compare to Gilead Sciences?

Summary

How does Curis compare to Vertex Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRIS vs. The Competition

Curis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Curis (CRIS) Competitors

CRIS vs. SGMO, BOLT, AMGN, GILD, and VRTX

How does Curis compare to Sangamo Therapeutics?

Does the media favor CRIS or SGMO?

Do analysts prefer CRIS or SGMO?

Is CRIS or SGMO more profitable?

Do institutionals & insiders have more ownership in CRIS or SGMO?

Which has more risk and volatility, CRIS or SGMO?

Which has better valuation and earnings, CRIS or SGMO?

Summary

How does Curis compare to Bolt Biotherapeutics?

Which has preferable earnings and valuation, CRIS or BOLT?

Do analysts recommend CRIS or BOLT?

Which has more risk & volatility, CRIS or BOLT?

Do institutionals & insiders hold more shares of CRIS or BOLT?

Does the media favor CRIS or BOLT?

Is CRIS or BOLT more profitable?

Summary

How does Curis compare to Amgen?

Which has more volatility & risk, AMGN or CRIS?

Which has better earnings & valuation, AMGN or CRIS?

Do insiders & institutionals believe in AMGN or CRIS?

Does the media prefer AMGN or CRIS?

Do analysts recommend AMGN or CRIS?

Is AMGN or CRIS more profitable?

Summary

How does Curis compare to Gilead Sciences?

Is CRIS or GILD more profitable?

Which has higher valuation and earnings, CRIS or GILD?

Which has more risk & volatility, CRIS or GILD?

Do analysts prefer CRIS or GILD?

Does the media refer more to CRIS or GILD?

Do insiders and institutionals hold more shares of CRIS or GILD?

Summary

How does Curis compare to Vertex Pharmaceuticals?

Does the media refer more to CRIS or VRTX?

Is CRIS or VRTX more profitable?

Which has more volatility & risk, CRIS or VRTX?

Do analysts recommend CRIS or VRTX?

Do institutionals and insiders believe in CRIS or VRTX?

Which has higher earnings & valuation, CRIS or VRTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRIS vs. The Competition

Curis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools